Gosset Ownership
Private
Employees
~50
Therapeutic Areas
Stage
NDA
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Rhoshan Pharmaceuticals General Information
Rhoshan Pharmaceuticals is developing RHO-11, an injectable aspirin formulation focused on early treatment of heart disease and stroke. FDA approval was expected in 2023 according to older information.
Contact Information
Primary Industry
Biotech
Corporate Office
Chadds Ford, Pennsylvania
United States
United States
Drug Pipeline
acetylsalicylic acid
NDAKey Partnerships
Rhoshan Pharmaceuticals Funding
No funding data available
To view Rhoshan Pharmaceuticals's complete valuation and funding history, request access »